Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	63 children with serologically confirmed dengue shock syndrome receiving intravenous fluids	Secondary infections with methylprednisolone with placebo
RCT	63 children with serologically confirmed dengue shock syndrome receiving intravenous fluids	Adverse effects 2 weeks with methylprednisolone with placebo
RCT	26 children with serologically confirmed dengue shock syndrome receiving intravenous fluids	Infection of the cut-down site 2/7 (28%) with hydrocortisone 0/19 (0%) with no hydrocortisone
RCT	26 children with serologically confirmed dengue shock syndrome receiving intravenous fluids	Bleeding from the cut-down site 4/7 (57%) with hydrocortisone 8/19 (42%) with no hydrocortisone
RCT	26 children with serologically confirmed dengue shock syndrome receiving intravenous fluids	Gastrointestinal bleeding 6/7 (86%) with hydrocortisone 7/19 (37%) with no hydrocortisone